ArticleCancer gene therapy2026
A p53 peptide mucosal vaccine induces cellular and humoral immunity and anti-tumor effects in a murine colorectal cancer model.
Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fundamentals and emerging frontiers in p53-targeted drug development.Biochemistry and biophysics reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many patients with metastatic and recurrent colorectal cancer (CRC) have poor outcomes, due to resistance to current treatment approaches. Missense mutations in the TP53 gene are found in about 65% of CRCs, but no current treatment approach targets mutant TP53 activity. To develop a vaccine approach against CRCs expressing a mutant p53 protein, we used a murine CRC model with conditional expression of a Trp53 codon R270H missense allele, and immunized mice with the experimental vaccine, which combined a synthetic R270H p53 peptide and wild-type p53 recombinant protein with a mucosal nanoemulsion (NE) adjuvant. The p53/NE vaccine was administered intranasally to the mice after mutant p53 induction and tumor initiation. Vaccinated mice had markedly increased serum anti-p53 IgG, IgG2a, and IgG2b as compared to control mice. The vaccination also enhanced antigen-specific Th1 and Th17 cellular immune responses, as shown by increasing production of IFNγ, IL-17a and IL-2. The immunized animals had significantly decreased tumor size, prolonged survival and increased tumor CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.